This product is a nucleoside antiviral drug that has a selective inhibitory effect on a variety of herpes viruses (HSV). After acyclovir enters HSV-infected cells, it binds to the specific thymidylate kinase encoded by the virus and is rapidly converted into acyclosine monophosphate, which is then converted into acyclosine diphosphate by the cell guanylate kinase, and then converted into acyclosine triphosphate by other cell enzymes, and competes with guanylate triphosphate to infect herpes simplex virus DNA polymerase, thereby inhibiting viral DNA synthesis. Acyclovir triphosphate is a strong viral DNA polymerase inhibitor, which has an inhibitory effect on the DNA polymerase of five human herpes viruses, namely HSV-1, HSV-2, VZV, CMZ and EBV, and has no effect on normal cells. Its antiviral efficacy is 160 times stronger than that of adenosine.

This product is a nucleoside antiviral drug that has a selective inhibitory effect on a variety of herpes viruses (HSV). After acyclovir enters HSV-infected cells, it binds to the specific thymidylate kinase encoded by the virus and is rapidly converted into acyclosine monophosphate, which is then converted into acyclosine diphosphate by the cell guanylate kinase, and then converted into acyclosine triphosphate by other cell enzymes, and competes with guanylate triphosphate to infect herpes simplex virus DNA polymerase, thereby inhibiting viral DNA synthesis. Acyclovir triphosphate is a strong viral DNA polymerase inhibitor, which has an inhibitory effect on the DNA polymerase of five human herpes viruses, namely HSV-1, HSV-2, VZV, CMZ and EBV, and has no effect on normal cells. Its antiviral efficacy is 160 times stronger than that of adenosine.

This product is a nucleoside antiviral drug that has a selective inhibitory effect on a variety of herpes viruses (HSV). After acyclovir enters HSV-infected cells, it binds to the specific thymidylate kinase encoded by the virus and is rapidly converted into acyclosine monophosphate, which is then converted into acyclosine diphosphate by the cell guanylate kinase, and then converted into acyclosine triphosphate by other cell enzymes, and competes with guanylate triphosphate to infect herpes simplex virus DNA polymerase, thereby inhibiting viral DNA synthesis. Acyclovir triphosphate is a strong viral DNA polymerase inhibitor, which has an inhibitory effect on the DNA polymerase of five human herpes viruses, namely HSV-1, HSV-2, VZV, CMZ and EBV, and has no effect on normal cells. Its antiviral efficacy is 160 times stronger than that of adenosine.

This product is a nucleoside antiviral drug that has a selective inhibitory effect on a variety of herpes viruses (HSV). After acyclovir enters HSV-infected cells, it binds to the specific thymidylate kinase encoded by the virus and is rapidly converted into acyclosine monophosphate, which is then converted into acyclosine diphosphate by the cell's guanylate kinase. It is then converted into acyclosine triphosphate by other cell enzymes, and competes with guanylate triphosphate to infect herpes simplex virus DNA polymerase, thereby inhibiting viral DNA synthesis. Acyclovir triphosphate is a very strong viral DNA polymerase inhibitor, and has an inhibitory effect on the DNA polymerases of five human herpes viruses, namely HSV-1, HSV-2, VZV, CMZ and EBV. It has no effect on normal cells, and its antiviral efficacy is 160 times stronger than that of adenosine.